Creative Medical Technology Holdings Issues Mid-Year Update
Creative Medical Technology Holdings issued a mid-year update highlighting positive interim data for Olastrocel (CELZ-201), which demonstrated statistically significant improvements in disability and pain in the ADAPT trial for chronic lower back pain. The company also reported strong pilot results for its cell-free osteoarthritis program, Ultrasome™, where 93% of patients showed clinically meaningful improvements, and noted that the FDA cleared an expansion of the ADAPT trial for patients on low-dose opioids.
Key figures
- Drug Name
- Olastrocel (CELZ-201), Ultrasome™
- Phase Of Trial
- Phase 3 readiness
- Phoenix veteran target
- at least 1,000
- Adapt expansion enrollment
- 85%
- Ultrasome improvement rate
- 93%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.